PMID- 20089806 OWN - NLM STAT- MEDLINE DCOM- 20100422 LR - 20211203 IS - 1521-0103 (Electronic) IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 333 IP - 1 DP - 2010 Apr TI - Cyclosporine up-regulates Kruppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo. PG - 34-42 LID - 10.1124/jpet.109.163949 [doi] AB - Cyclosporine A (CSA, calcineurin inhibitor) has been shown to block both vascular smooth muscle cell (VSMC) proliferation in cell culture and vessel neointimal formation following injury in vivo. The purpose of this study was to determine molecular and pathological effects of CSA on VSMCs. Using real-time reverse transcription-polymerase chain reaction, Western blot analysis, and immunofluorescence microscopy, we show that CSA up-regulated the expression of Kruppel-like factor-4 (KLF4) in VSMCs. KLF4 plays a key role in regulating VSMC phenotypic modulation. KLF4 antagonizes proliferation, facilitates migration, and down-regulates VSMC differentiation marker gene expression. We show that the VSMC differentiation marker genes smooth muscle alpha-actin (ACTA2), transgelin (TAGLN), smoothelin (SMTN), and myocardin (MYOCD) are all down-regulated by CSA in VSMC monoculture, whereas cyclin-dependent kinase inhibitor-1A (CDKN1A) and matrix metalloproteinase-3 (MMP3) are up-regulated. CSA did not affect the abundance of the VSMC microRNA (MIR) markers MIR143 and MIR145. Administration of CSA to rat carotid artery in vivo resulted in acute and transient suppression of ACTA2, TAGLN, SMTN, MYOCD, and smooth muscle myosin heavy chain (MYH11) mRNA levels. The tumor suppressor genes KLF4, p53, and CDKN1A, however, were up-regulated, as well as MMP3, MMP9, and collagen-VIII. CSA-treated arteries showed remarkable remodeling, including breakdown of the internal elastic lamina and reorientation of VSMCs, as well as increased KLF4 immunostaining in VSMCs and endothelial cells. Altogether, these data show that cyclosporin up-regulates KLF4 expression and promotes phenotypic modulation of VSMCs. FAU - Garvey, Sean M AU - Garvey SM AD - Department of Medicine, Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA, USA. FAU - Sinden, Daniel S AU - Sinden DS FAU - Schoppee Bortz, Pamela D AU - Schoppee Bortz PD FAU - Wamhoff, Brian R AU - Wamhoff BR LA - eng GR - R01 HL081682/HL/NHLBI NIH HHS/United States GR - T32 GM007171/GM/NIGMS NIH HHS/United States GR - R01-HL081682/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20100120 PL - United States TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - 0 (Antigens, Differentiation) RN - 0 (Immunosuppressive Agents) RN - 0 (Klf4 protein, rat) RN - 0 (Kruppel-Like Factor 4) RN - 0 (Kruppel-Like Transcription Factors) RN - 83HN0GTJ6D (Cyclosporine) SB - IM MH - Animals MH - Antigens, Differentiation/metabolism MH - Aorta/cytology MH - Carotid Arteries/drug effects/pathology MH - Cell Differentiation MH - Cells, Cultured MH - Cyclosporine/adverse effects/*pharmacology MH - Down-Regulation MH - Immunosuppressive Agents/adverse effects/*pharmacology MH - Kruppel-Like Factor 4 MH - Kruppel-Like Transcription Factors/*biosynthesis MH - Myocytes, Smooth Muscle/cytology/*drug effects/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Tunica Media/drug effects/pathology MH - Up-Regulation PMC - PMC2846029 EDAT- 2010/01/22 06:00 MHDA- 2010/04/23 06:00 PMCR- 2011/04/01 CRDT- 2010/01/22 06:00 PHST- 2010/01/22 06:00 [entrez] PHST- 2010/01/22 06:00 [pubmed] PHST- 2010/04/23 06:00 [medline] PHST- 2011/04/01 00:00 [pmc-release] AID - jpet.109.163949 [pii] AID - 3572689 [pii] AID - 10.1124/jpet.109.163949 [doi] PST - ppublish SO - J Pharmacol Exp Ther. 2010 Apr;333(1):34-42. doi: 10.1124/jpet.109.163949. Epub 2010 Jan 20.